JMP reiterates Lifecore Biomedical at market outperform

Lifecore Biomedical was reiterated at a market outperform rating and a $17 price target by JMP Securities analyst Anthony Ostrea on the company's announcement of strong second-quarter 2006 results, reporting revenue of $15.2 million, above JMP's estimate of $14.8 million. Sales from the company's dental implant business are also up 9% from last year. Shares of the Chaska, Minn., biomedical company were down 74 cents, or 5.29%, at $13.25 on volume of 160,530 shares versus the three-month running average of 45,977 shares. (Nasdaq: LCBM).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.